Stock of the Day

Larimar Therapeutics (LRMR)

$3.19

-$0.08 (-2.4%)

Market Cap: $208.65M

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Recent News

• Larimar Therapeutics Inc. LRMR (U.S.: Nasdaq) (wsj.com)
• Larimar Therapeutics (LRMR) Gets a Buy from JMP Securities (markets.businessinsider.com)